FDA authorizes a new treatment for Covid. The drug is expected to fight the Omicron.
Where: United States
The Facts
The US Food and Drug Administration(FDA) has issued an emergency use authorization for a monoclonal antibody treatment that is effective against the Omicron variant of the Covid-19 virus.
The FDA news release states, “Bebtelovimab works by binding to the spike protein of the virus that causes COVID-19.”
An Eli Lilly news release states, “Pseudovirus and authentic virus testing demonstrate that bebtelovimab retains full neutralizing activity against Omicron – currently the predominant variant in the US.”
Lilly has signed an agreement with the US government to supply approximately 600,000 doses of bebtelovimab.
Treatment with the new drug has not been studied in patients with Covid-19 who are hospitalized.
Primary Sources
Direct, authoritative source material on this story.
Reference Articles
Articles Citable has ingested related to this story.
Reference Articles
Articles Citable has ingested related to this story.
Media Coverage
Why did we include this story
Most covered story by the media today
of articles referenced this story
Coverage by Media Outlet
Media outlets covering this story along with their positive or negative sentiment toward this story.
